Martin & Harris focuses on the manufacturing of pharmaceutical formulations, medicinal chemicals, and botanical products, with a strong emphasis on quality, compliance, and innovation. Alongside its core operations, the company also allocates capital into financial instruments such as equities and mutual funds, generating additional income streams.

Business Divisions

The company operates through two major verticals:

1. Pharmaceutical Segment (52% of Revenue)
This core division involves the production of a wide range of pharmaceutical products that adhere to global quality standards. The company serves multiple therapeutic categories, strengthening its presence across both domestic and international markets.

2. Investment & Derivative Segment (48% of Revenue)
In addition to pharmaceuticals, Martin & Harris has developed a diversified investment portfolio comprising mutual funds, and both listed and unlisted equities. This segment not only enhances returns but also helps in balancing overall business risk.

The company continues to upgrade its manufacturing facilities in Roorkee and Una to meet evolving global standards and industry requirements.

Financial Highlights
Revenue Performance: The company reported revenue of ₹146 million in the latest fiscal year. While slightly lower than ₹205 million in the previous year, it continues to demonstrate stable revenue generation across its segments.
Healthy Margins: Gross margins remained strong at 71.92%, reflecting efficient cost control and a resilient product mix.
Operational Performance: EBITDA stood at ₹26 million. Although lower than the previous year’s ₹72 million, it still indicates solid operational capability despite increased expenses.
Profitability: Net profit was ₹40 million, with a healthy margin of 27.4%, showcasing the company’s ability to sustain profitability even amid challenges.
Earnings Per Share (EPS): EPS came in at ₹100.25, indicating strong value generation for shareholders. With a relatively low valuation multiple, the company presents an attractive proposition compared to many industry peers.

Pros
Established Brand Legacy: Long-standing presence enhances credibility and trust in the market.
Diversified Revenue Model: Balanced income from pharmaceuticals and investments supports stability.
Focus on Innovation: Continuous product development and industry recognition strengthen its competitive edge.

Cons
Domestic Market Dependence: Heavy reliance on the Indian market exposes the business to local risks.
Volatile Investment Income: Returns from financial investments may fluctuate with market conditions.
Operational Challenges: Ongoing investment is required to maintain and upgrade manufacturing infrastructure.